Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Oncology: State-of-the-Art Research in France
share announcement

Oncology: State-of-the-Art Research in France

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 June 2024 | Viewed by 4288

Special Issue Editor

Prof. Dr. Thierry Magnaldo

E-Mail
Guest Editor
Genetics and Physiopathology of Epithelial Cancers, Institute for Research on Cancer and Aging, UMR CNRS 7284 INSERM U1081 UNS, Faculté de médecine, Université Côte d'Azur, Nice, France
Interests: skin squamous cell carcinoma; skin cancers; stem cells; stromal–epithelial interactions

Special Issue Information

Dear Colleagues,

This Special Issue welcomes high-quality papers on cancer in France. In this Special Issue, we aim to present state-of-the-art research in France. We welcome submissions that cover all types of studies and stages of cancer, from basic laboratory research to translational and clinical research, including cohort studies, randomized controlled trials, and epidemiological studies. Comprehensive reviews that describe the history and significant contributions to cancer research in France are also welcome.

Prof. Dr. Thierry Magnaldo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2735 KiB  
Article
A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort
by Maryam Karimi, Sebastian Mendez-Pineda, Hélène Blanché, Anne Boland, Céline Besse, Jean-François Deleuze, Xiang-Yu Meng, Nanor Sirab, Karine Groussard, Thierry Lebret, Julia Bonastre, Yves Allory, François Radvanyi, Simone Benhamou and Stefan Michiels
Cancers 2023, 15(17), 4218; https://doi.org/10.3390/cancers15174218 - 23 Aug 2023
Viewed by 998
Abstract
Bladder cancer (BC) is the 6th most common cancer worldwide, with tobacco smoking considered as its main risk factor. Accumulating evidence has found associations between genetic variants and the risk of BC. Candidate gene-environment interaction studies have suggested interactions between cigarette smoking and [...] Read more.
Bladder cancer (BC) is the 6th most common cancer worldwide, with tobacco smoking considered as its main risk factor. Accumulating evidence has found associations between genetic variants and the risk of BC. Candidate gene-environment interaction studies have suggested interactions between cigarette smoking and NAT2/GSTM1 gene variants. Our objective was to perform a genome-wide association case-only study using the French national prospective COBLAnCE cohort (COhort to study BLAdder CancEr), focusing on smoking behavior. The COBLAnCE cohort comprises 1800 BC patients enrolled between 2012 and 2018. Peripheral blood samples collected at enrolment were genotyped using the Illumina Global Screening Array with a Multi-Disease drop-in panel. Genotyping data (9,719,614 single nucleotide polymorphisms (SNP)) of 1674, 1283, and 1342 patients were analyzed for smoking status, average tobacco consumption, and age at smoking initiation, respectively. A genome-wide association study (GWAS) was conducted adjusting for gender, age, and genetic principal components. The results suggest new candidate loci (4q22.1, 12p13.1, 16p13.3) interacting with smoking behavior for the risk of BC. Our results need to be validated in other case-control or cohort studies. Full article
(This article belongs to the Special Issue Oncology: State-of-the-Art Research in France)
►▼ Show Figures

Figure 1

14 pages, 2513 KiB  
Article
Fat-Containing Soft Tissue Tumors in Children, Adolescents, and Young Adults: Which Require Biopsy?
by Liesbeth Cardoen, Nayla Nicolas, Violette Le Gaudu, Arnaud Gauthier, Matthieu Carton, Dominique Berrebi, Joanna Cyrta, Charlotte Collignon, Camille Cordero, Gaëlle Pierron, Stéphanie Pannier, Pascale Philippe-Chomette, Daniel Orbach and Hervé J. Brisse
Cancers 2023, 15(12), 3228; https://doi.org/10.3390/cancers15123228 - 17 Jun 2023
Viewed by 1168
Abstract
Purpose: To confirm the overall benignity of fat-containing soft tissue tumors (STT) on a pediatric cohort and to define the clinical and imaging features that warrant a biopsy. Methods: A retrospective monocentric study was conducted on patients aged less than 25 years consecutively [...] Read more.
Purpose: To confirm the overall benignity of fat-containing soft tissue tumors (STT) on a pediatric cohort and to define the clinical and imaging features that warrant a biopsy. Methods: A retrospective monocentric study was conducted on patients aged less than 25 years consecutively referred for fat-containing STT to our Comprehensive Cancer Center between 1998 and 2022. Tumor imaging characteristics at diagnosis (US, CT, or MRI) were correlated with pathology. Results: The database extraction identified 63 fat-containing tumors with clinical, histologic, and imaging data available for review. In total, 58 (92%) were benign tumors: 36 lipoblastomas and lipomas, 12 fibrous hamartomas of infancy (FHI), 5 lipofibromatosis, 2 lipomas arborescens, 2 lipomatosis and 1 spindle-cell lipoma. Five patients (8%) were diagnosed with liposarcoma. Factors significantly correlated with malignancy were age >10 years old (p < 0.001), having a cancer-predisposing condition (p < 0.001), a percentage of fat <25% (p = 0.002), and a presence of myxoid zones (p < 0.001) on imaging. Conclusion: Most fat-containing STT in children may be classified as benign tumors based on clinics and imaging. The indication for biopsy could be limited to patients aged 10 years or more with either a cancer-predisposing condition or imaging features demonstrating either a low-fat component (<25%) or the presence of myxoid zones. Full article
(This article belongs to the Special Issue Oncology: State-of-the-Art Research in France)
►▼ Show Figures

Graphical abstract

14 pages, 2818 KiB  
Article
The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies
by Alain Sarasin
Cancers 2023, 15(10), 2706; https://doi.org/10.3390/cancers15102706 - 10 May 2023
Viewed by 1550
Abstract
Background: Xeroderma pigmentosum (XP) is a rare genetic disorder characterized by a high incidence of skin cancers. These patients are deficient in nucleotide excision repair caused by mutations in one of the 7 XP genes. Methods: We diagnosed 181 XP patients using UV-induced [...] Read more.
Background: Xeroderma pigmentosum (XP) is a rare genetic disorder characterized by a high incidence of skin cancers. These patients are deficient in nucleotide excision repair caused by mutations in one of the 7 XP genes. Methods: We diagnosed 181 XP patients using UV-induced DNA repair measurements and/or DNA sequencing from 1982 to 2022 in France. Results: As all XP patients, the French ones are very sensitive to UV exposure but since they are usually very well protected, they develop relatively few skin cancers. A majority of French XP patients originate from North Africa and bear a founder mutation on the XPC gene. The striking discovery is that these patients are at a very high risk to develop aggressive and lethal internal tumors such as hematological malignancies (more than a 100-fold risk compared to the general population for myelodysplasia/leukemia) with a median age of death of 25 years, and brain, gynecological, and thyroid tumors with even lower median ages of death. The high mutation rates found in XP-C internal tumors allow us to think that these XP patients could be successfully treated by immunotherapies. A full analysis of the molecular origins of these DNA repair-deficient tumors is discussed. Several explanations for this high predisposition risk are proposed. Conclusions: As the age of the XP population is increasing due to better photo-protection, the risk of lethal internal tumors is a new Damocles sword that hangs over XP-C patients. This review of the French cohort is of particular importance for alerting physicians and families to the prevention and early detection of aggressive internal tumors in XP patients. Full article
(This article belongs to the Special Issue Oncology: State-of-the-Art Research in France)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop